Internal Medicine
NAFLD / MASLD
Internal Medicine
Well covered in the main question banks · 34 main-bank entries · 16 linked PDF entries · 0 generated drills
Prerequisites and related lessons
- Liver function tests (LFT)
Curriculum reference · Official College Textbook – Digestive Disorders – Part 2, pp. 130–133. Lesson adapted from Internal Medicine and Tropical Medicine.
Topic map
- Steatosis plus metabolic riskMASLD terminology
- Mechanisminsulin resistance and lipotoxic injury
- StratifyFIB-4 followed by elastography/ELF as needed
- Treatlifestyle, comorbidities and selected fibrosis-directed therapy
Scroll the diagram to see all labels.
Definition, risks and mechanism
The course uses NAFLD and NASH. Current terminology commonly uses metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). MASLD requires hepatic steatosis plus cardiometabolic risk, with alcohol exposure and competing causes assessed. It is closely associated with obesity, insulin resistance, type 2 diabetes, hypertension and dyslipidemia [IM Mid Q2/Q4 · IM Dept Q1]. Type 1 diabetes is the exam exception to the typical metabolic profile, but does not exclude steatotic disease in a person with metabolic risks.
Insulin resistance [IM Dept Q3] increases fatty-acid delivery, lipogenesis and profibrotic signaling. Oxidative stress, inflammation and hepatocyte injury promote fibrosis. Histology ranges from steatosis to MASH with ballooning and lobular inflammation, then fibrosis and cirrhosis. Fibrosis stage predicts liver outcomes. Most patients are asymptomatic or have incidental enzymes and hepatomegaly. Early disease may have ALT greater than AST [IM Dept Q2]. AST:ALT >2 can suggest alcohol-associated disease in context. Neither ratio nor normal enzymes exclude fibrosis.
Detection, staging and differential
- Initial assessment
- Assess metabolic risk, steatosis and alternate causes
- Confirmation or next test
- FIB-4 followed by VCTE/ELF when indicated; selective biopsy
The course keys ultrasound showing steatosis and exclusion of other causes [IM Mid Q1]. Standard ultrasound can miss mild steatosis, especially in obesity, and does not stage MASH. CT may incidentally show fat; CAP or MRI-PDFF can estimate steatosis. Review alcohol, drugs and alternative causes (viral, autoimmune, Wilson or other inherited disorders as indicated). Assess glucose/A1c, lipid profile, blood pressure, weight and other risk factors. In a typical at-risk adult, FIB-4 <1.3 supports low advanced-fibrosis risk; ≥1.3 often warrants VCTE or ELF. >2.67 or persistently abnormal chemistry raises referral priority. Adjust interpretation in adults >65, age <35 and acute illness. Elastography estimates liver stiffness rather than proving histologic inflammation. Biopsy is selective when staging or distinction from another process will change management.
Lifestyle, medications and follow-up
Encourage activity, a sustainable energy deficit where appropriate and cardiometabolic risk treatment. The book cites 0.5–1 kg per week and 7–9% weight loss [IM Dept Q4–5]. Guideline targets are commonly ≥5% for steatosis, 7–10% for inflammation and ≥10% for fibrosis improvement, when safely achievable. Manage diabetes, lipids, blood pressure and obesity. Statins can be used for cardiovascular indications in appropriate patients. Metformin is for metabolic indications rather than MASH histology treatment.
The department asks about orlistat, an enteric lipase inhibitor [IM Dept Q6–8], continuing only when >5% weight is lost at 3 months under the course regimen, and risk of fat-soluble vitamin deficiency. It is a weight-management option in selected patients, not universal MASH therapy. Pioglitazone [IM Dept Q9] and vitamin E 800 IU/day [IM Dept Q10] are textbook choices in selected settings, with individualized benefit/risk. Current practice may use obesity or diabetes medication, bariatric surgery in eligible patients, and locally approved MASH-targeted therapies for selected noncirrhotic patients with significant fibrosis. Monitor and refer according to fibrosis risk.
Cardiovascular disease is a major cause of morbidity. Cirrhosis can progress to portal hypertension and HCC; provide cirrhosis-based surveillance, including HCC surveillance typically every six months, and transplant assessment when appropriate. The textbook provides historical cohort incidence and recurrence estimates with limited generalizability.
Exam traps
Steatosis on ultrasound does not prove inflammation or fibrosis. “Normal ALT” is compatible with advanced disease. The course’s older drug and weight figures are exam anchors; management uses current indications and disease stage.
Diagnostic and management pathways
- Steatosis or metabolic risk → review alcohol and alternate causes
- Assess cardiometabolic risk and FIB-4
- Indeterminate/high risk → elastography or ELF and specialist assessment as indicated
- Treat lifestyle/comorbidities, consider eligible targeted care, and surveil established cirrhosis
Compare at a glance
| Stage or test | What it shows | What guides care |
|---|---|---|
| Steatosis | Fat signal on imaging | Metabolic risk and fibrosis screening |
| MASH | Steatosis plus ballooning and inflammation | Selected histology or validated clinical staging |
| Fibrosis | Scarring estimated by FIB-4, ELF or stiffness | Escalate staging and treatment by risk |
| Cirrhosis | Advanced scarring and portal hypertension risk | HCC and decompensation surveillance |
Supplementary clarification – not directly stated in the uploaded materials. Clinical references · EASL–EASD–EASO MASLD guideline · AASLD assessment and management guidance
Exam words
- obesity, insulin resistance, type 2 diabetes, hypertension and dyslipidemia [IM Mid Q2/Q4 · IM Dept Q1]
- Insulin resistance [IM Dept Q3]
- ALT greater than AST [IM Dept Q2]
- ultrasound showing steatosis and exclusion of other causes [IM Mid Q1]
- 0.5–1 kg per week and 7–9% weight loss [IM Dept Q4–5]
- orlistat, an enteric lipase inhibitor [IM Dept Q6–8]
- Pioglitazone [IM Dept Q9]
- vitamin E 800 IU/day [IM Dept Q10]
Practice questions
Rapid revision sheet
Sixty-second recall. Say the definition, the key clue and the next clinical step out loud before checking the list.
- obesity, insulin resistance, type 2 diabetes, hypertension and dyslipidemia [IM Mid Q2/Q4 · IM Dept Q1]
- Insulin resistance [IM Dept Q3]
- ALT greater than AST [IM Dept Q2]
- ultrasound showing steatosis and exclusion of other causes [IM Mid Q1]
- 0.5–1 kg per week and 7–9% weight loss [IM Dept Q4–5]
- orlistat, an enteric lipase inhibitor [IM Dept Q6–8]
Official College Textbook – Digestive Disorders – Part 2, pp. 130–133
Active recall
In metabolic fatty liver disease, what feature best predicts liver-related progression?
Fibrosis stage. Finding steatosis should lead to fibrosis risk assessment, typically starting with a noninvasive tool in appropriate adults.
Official College Textbook – Digestive Disorders – Part 2, pp. 130–133
Recall the diagnostic and management pathway from memory.
Start with the presenting clue, name the first assessment, then distinguish confirmation, immediate management and follow-up.
- Steatosis or metabolic risk → review alcohol and alternate causes
- Assess cardiometabolic risk and FIB-4
- Indeterminate/high risk → elastography or ELF and specialist assessment as indicated
- Treat lifestyle/comorbidities, consider eligible targeted care, and surveil established cirrhosis